Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tanuja Puri

Nurse Practitioner Torrance, CA Nurse Practitioner

NPI 1508023524 CMS profile 10840033

23451 Madison St Ste 290, Torrance, CA 90505

Open in the dashboard

General payments

$4,456

161 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tanuja Puri of Torrance, CA is reported in the CMS Open Payments database as having received $4,456 across 161 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,395 28
2024 General $796 35
2023 General $997 47
2022 General $771 34
2021 General $496 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tanuja Puri
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Tanuja Puri were reported at $1,395. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Tanuja Puri Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $496 $135 $40–$426 $132
2022 $771 $152 $48–$470 $149
2023 $997 $166 $54–$529 $160
2024 $796 $173 $55–$556 $164
2025 $1,395 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,340 107 payments
  2. Janssen Biotech, Inc. $1,167 15 payments
  3. Intercept Pharmaceuticals, Inc. $156 9 payments
  4. Aimmune Therapeutics, Inc. $132 6 payments
  5. E.R. Squibb & Sons, L.L.C. $125 1 payment
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $94 2 payments
  7. Gilead Sciences, Inc. $77 3 payments
  8. Nestle HealthCare Nutrition Inc. $62 3 payments
  9. Phathom Pharmaceuticals, Inc. $60 3 payments
  10. Ipsen Biopharmaceuticals, Inc $51 2 payments
  11. Other $191 10 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,683 157 payments
  2. Travel and Lodging $555 1 payment
  3. Education $218 3 payments
Products named General payments · program years 2021–2025
  1. SKYRIZI Immunology $1,028 47 payments
  2. TREMFYA $779 3 payments
  3. RINVOQ $558 28 payments
  4. STELARA $389 12 payments
  5. SKYRIZI Immunology $330 8 payments
  6. CREON $329 26 payments
  7. LINZESS $275 24 payments
  8. HUMIRA $225 7 payments
  9. ZENPEP $194 9 payments
  10. ZEPOSIA $141 2 payments
  11. Other $817 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

597

Median for Nurse Practitioner: 389

Drug cost

$49,410

Median for Nurse Practitioner: $21,885

Branded share of claims

63.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 26 $34,541
Lubiprostone Generic 19 $5,828
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 257 $3,884
Famotidine Generic 98 $1,468
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 26 $1,453
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 70 $1,133
Omeprazole Generic 71 $908
Pantoprazole Sodium Generic 19 $136
Dicyclomine Hcl Generic 11 $59

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $274
$274 — —
RINVOQ
  • AbbVie, Inc. $152
$152 — —
STELARA
  • Janssen Biotech, Inc. $119
$119 — —
CREON
  • AbbVie, Inc. $70
$70 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

161 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record